Publication | Open Access

Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product

Malignant DiseaseMalignant MesotheliomaMalignant Blood DisorderImmunologyPathologyAntisense TherapyAnti-cancer AgentMedicineRadiation OncologyBcl-xl Gene ProductTumor Microenvironment